First Human Trial of COVID-19 Vaccine Found Safe and Induces Rapid Immune Response |
|
New research published in The Lancet reports that the first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans. The open-label trial in 108 healthy adults showed promising results after 28 days, while the final results will be evaluated in six months. Further trials are needed to tell whether the immune response that the vaccine elicits effectively protects against SARS-CoV-2 infection.
|
|
|
|
|
|
|
|
|
A biweekly update on gene editing research, regulations, and impact
produced by ISAAA Inc. |
|
|
|
|
A monthly update on gene drive research and development provided by ISAAA in collaboration with the Outreach Network for Gene Drive Research |
|
|
|
|
GM APPROVAL UPDATES |
- The Philippines approved the canola event LBFLFK for food, feed, and processing.
- The Philippines approved the cotton event GFM cry1A for commercial cultivation.
- Brazil approved the wheat event HB4 for commercial cultivation.
- The Philippines approved the soybean event GMB 151 for food, feed, and processing.
- The Philippines approved the eggplant event EE-1 for cultivation
- The USA approved the canola event MON94100 for food and feed.
|
|
|
|
Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10. |
|
|
|